KR100988233B1 - 클로피도그렐 1,5-나프탈렌 다이술폰산 염 또는 이의수화물의 약학 조성물 및 제제 - Google Patents
클로피도그렐 1,5-나프탈렌 다이술폰산 염 또는 이의수화물의 약학 조성물 및 제제 Download PDFInfo
- Publication number
- KR100988233B1 KR100988233B1 KR1020070137453A KR20070137453A KR100988233B1 KR 100988233 B1 KR100988233 B1 KR 100988233B1 KR 1020070137453 A KR1020070137453 A KR 1020070137453A KR 20070137453 A KR20070137453 A KR 20070137453A KR 100988233 B1 KR100988233 B1 KR 100988233B1
- Authority
- KR
- South Korea
- Prior art keywords
- acid
- clopidogrel
- pharmaceutical composition
- nafadisylate
- group
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Abstract
Description
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070137453A KR100988233B1 (ko) | 2007-12-26 | 2007-12-26 | 클로피도그렐 1,5-나프탈렌 다이술폰산 염 또는 이의수화물의 약학 조성물 및 제제 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070137453A KR100988233B1 (ko) | 2007-12-26 | 2007-12-26 | 클로피도그렐 1,5-나프탈렌 다이술폰산 염 또는 이의수화물의 약학 조성물 및 제제 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090069703A KR20090069703A (ko) | 2009-07-01 |
KR100988233B1 true KR100988233B1 (ko) | 2010-10-18 |
Family
ID=41321316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070137453A KR100988233B1 (ko) | 2007-12-26 | 2007-12-26 | 클로피도그렐 1,5-나프탈렌 다이술폰산 염 또는 이의수화물의 약학 조성물 및 제제 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100988233B1 (ko) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2939082C (en) | 2014-02-13 | 2022-06-07 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
ME03580B (me) | 2014-02-13 | 2020-07-20 | Incyte Corp | Ciklopropilamini kao lsd1 inhibitori |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
CN104644595B (zh) * | 2015-03-09 | 2017-10-24 | 吕霄芳 | 一种含有氯吡格雷的固体药物组合物 |
TWI714567B (zh) | 2015-04-03 | 2021-01-01 | 美商英塞特公司 | 作為lsd1抑制劑之雜環化合物 |
CR20180152A (es) | 2015-08-12 | 2018-08-09 | Incyte Corp | Sales de un inhibidor de lsd1 |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050099445A (ko) * | 2004-04-09 | 2005-10-13 | 한미약품 주식회사 | 결정성 클로피도그렐 나프탈렌술폰산염 또는 이의 수화물,이의 제조방법 및 이를 함유하는 약학적 조성물 |
KR20070002702A (ko) * | 2005-06-30 | 2007-01-05 | 주식회사 씨티씨바이오 | 클로피도그렐 유리염기 함유 조성물 |
KR20070023185A (ko) * | 2005-08-23 | 2007-02-28 | 에스케이케미칼주식회사 | S-(+)-클로피도그렐 헤미나파디실레이트 염 및 그의제조방법 |
-
2007
- 2007-12-26 KR KR1020070137453A patent/KR100988233B1/ko active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050099445A (ko) * | 2004-04-09 | 2005-10-13 | 한미약품 주식회사 | 결정성 클로피도그렐 나프탈렌술폰산염 또는 이의 수화물,이의 제조방법 및 이를 함유하는 약학적 조성물 |
KR20070002702A (ko) * | 2005-06-30 | 2007-01-05 | 주식회사 씨티씨바이오 | 클로피도그렐 유리염기 함유 조성물 |
KR100684099B1 (ko) | 2005-06-30 | 2007-02-16 | 주식회사 씨티씨바이오 | 클로피도그렐 유리염기 함유 조성물 |
KR20070023185A (ko) * | 2005-08-23 | 2007-02-28 | 에스케이케미칼주식회사 | S-(+)-클로피도그렐 헤미나파디실레이트 염 및 그의제조방법 |
Also Published As
Publication number | Publication date |
---|---|
KR20090069703A (ko) | 2009-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100988233B1 (ko) | 클로피도그렐 1,5-나프탈렌 다이술폰산 염 또는 이의수화물의 약학 조성물 및 제제 | |
KR101665705B1 (ko) | 안정성이 개선된 필름 코팅 제제 | |
US7182958B1 (en) | β-carboline pharmaceutical compositions | |
TWI389691B (zh) | 可口服且具有活性成分快速釋出之固態醫藥劑型 | |
EP2654736B1 (en) | Novel pharmaceutical composition | |
EP2442799B2 (en) | Solid pharmaceutical composition comprising rivaroxaban | |
TWI428151B (zh) | 含有甘露醇或乳糖之固形製劑 | |
KR101647842B1 (ko) | 저장 안정성이 개선된 의약 조성물 | |
JP5322039B2 (ja) | フェニルアラニン誘導体の徐放性経口投与製剤 | |
WO2010094471A1 (en) | Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation | |
US20050202081A1 (en) | Stable pharmaceutical compositions comprising ace inhibitor(s) | |
US20130236544A1 (en) | Stable pharmaceutical compositions of fesoterodine | |
CA2435714C (en) | Fenofibrate tablets | |
WO2011135580A2 (en) | Pharmaceutical compositions of sirolimus | |
US20090270448A1 (en) | Pharmaceutical formulations comprising clopidogrel | |
EP2266541A1 (en) | Solid pharmaceutical composition comprising rivaroxaban | |
KR20150138104A (ko) | 베포타스틴과 글리세릴베헤네이트를 포함하는 약제학적 제제 | |
PL191767B1 (pl) | Stabilizowane przed racemizacją stałe lub ciekłe preparaty farmaceutyczne zawierające jako składnik czynny cilansetron, sposób wytwarzania stabilizowanych przed racemizacją stałych preparatów farmaceutycznych zawierających jako składnik czynny cilansetron oraz zastosowanie dopuszczalnych fizjologicznie rozpuszczalnych w wodzie kwaśnych dodatków | |
EP2095815B1 (en) | Pharmaceutical formulations containing clopidogrel | |
CA3057820C (en) | Tableted medicinal composition comprising nalfurafine | |
WO2020111089A1 (ja) | 医薬組成物 | |
JP2012180280A (ja) | 貯蔵安定性が改善された固形製剤 | |
JPWO2007046411A1 (ja) | イソキサゾール化合物の安定化方法 | |
KR101956586B1 (ko) | 약제학적 조성물 및 이의 제조방법 | |
CA2695040A1 (en) | Stable pharmaceutical composition of a water-soluble vinorelbine salt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130924 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140917 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150915 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20160912 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170928 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20181004 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20191001 Year of fee payment: 10 |